PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

NCT04624984 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma
Refractory or Relapsed Classical Hodgkin Lymphoma

Interventions

DRUG: PD-1 inhibitor
DRUG: PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome

Sponsor

Sun Yat-sen University